株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

中枢神経系治療薬の世界市場:疾患別・地域別・国別 - 市場機会と将来予測

Global Central Nervous System Therapeutic Market : Analysis By Disease, By Region, By Country : Opportunities and Forecast - By Region, By Country

発行 Azoth Analytics 商品コード 817528
出版日 ページ情報 英文 214 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.00円で換算しております。
Back to Top
中枢神経系治療薬の世界市場:疾患別・地域別・国別 - 市場機会と将来予測 Global Central Nervous System Therapeutic Market : Analysis By Disease, By Region, By Country : Opportunities and Forecast - By Region, By Country
出版日: 2019年03月31日 ページ情報: 英文 214 Pages
概要

当レポートでは、世界の中枢神経系 (CNS) 治療薬の市場について分析し、全体的な市場規模の動向見通し (過去5年間分・今後6年間分) や、疾患別・地域別 (主要国) の詳細動向、主な市場促進・抑制要因、市場の求心力と競争環境、企業プロファイルなどについて調査しております。

第1章 分析手法

第2章 エグゼクティブ・サマリー

第3章 戦略提言

第4章 中枢神経系 (CNS) 治療薬市場:製品の概要

第5章 世界の中枢神経系治療薬市場:成長率とその予測

  • 市場規模の実績値 (金額ベース、過去5年間分)
  • 市場規模の予測値 (金額ベース、今後6年間分)

第6章 世界の中枢神経系治療薬市場:部門別 (疾患別) の分析

  • 市場規模・シェア:疾患別
    • 疾患別市場シェア:実績値 (金額ベース)
    • 疾患別市場シェア:予測値 (金額ベース)
  • がん
  • 神経血管障害
  • 神経変性疾患
  • 神経症 (メンタルヘルス)
  • 外傷
  • 感染症

第7章 世界の中枢神経系治療薬市場:地域別の分析

  • 市場規模・シェア:地域別
    • 地域別市場シェア:実績値 (金額ベース)
    • 地域別市場シェア:予測値 (金額ベース)
  • 北米市場:成長率とその予測 - 地域全体
    • 市場規模:実績値 (金額ベース、過去5年間分)
    • 市場規模:予測値 (金額ベース、今後6年間分)
    • 市場規模、種類別:実績値 (金額ベース、過去5年間分)
    • 市場規模、種類別:予測値 (金額ベース、今後6年間分)
  • 北米市場:成長率とその予測 - 米国、カナダ
    • 各国の市場規模 (金額ベース、通算11年間分)
  • 欧州市場:成長率とその予測 - 地域全体
  • 欧州市場:成長率とその予測 - 英国、ドイツ
  • アジア太平洋地域市場:成長率とその予測 - 地域全体
  • アジア太平洋地域市場:成長率とその予測 - 中国、日本、インド
  • 他の国々 (RoW) の市場:成長率とその予測 - 地域全体
  • 他の国々 (RoW) の市場:成長率とその予測 - ブラジル

第8章 市場のダイナミクス:世界の中枢神経系治療薬市場

  • 市場促進要因
  • 市場抑制要因

第9章 市場動向:世界の中枢神経系治療薬市場

第10章 ポーターのファイブフォース分析

第11章 SWOT分析

第12章 サプライチェーン分析

第13章 政策・規制環境

第14章 企業プロファイル

  • Biogen
  • Pfizer
  • Teva Pharmaceuticals
  • Novartis
  • Johnson & Johnson
  • Shire
  • Merck & Co.
  • AstraZeneca
  • 大塚製薬
  • Eli Lilly
図表

List of Figures

  • Figure 1: Flowchart of Nervous System
  • Figure 2: Tumor Grade Descriptions
  • Figure 3: Overview of major subcategories of central nervous system disorders
  • Figure 4: Global Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 5: Global Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
  • Figure 6: Global Overweight Population (Age above 18), 2015-2018 (% of total)
  • Figure 7: Global Overweight Population (Age above 18), By Sex, 2018 (% of total)
  • Figure 8: Smoking Prevalence Among Adults, By Gender, 2015
  • Figure 9: Cigarette Sales Share, By Region, 2017 (% of total)
  • Figure 10: Distributions of persons aged 60 years or above by region in millions, 2015 and 2030F
  • Figure 11: Global Aged Population (Above 65), 2014-2018 (% of total)
  • Figure 12: Regions with dedicated policies for neurological disorders, In 2017, ( In %)
  • Figure 13: Countries with dedicated policies for neurological disorders, Based on income group, In 2017, In %
  • Figure 14: Healthcare Expenditure (Share of GDP), By Selected Country, 2014-2018 (In %)
  • Figure 15: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
  • Figure 16: Expected Global Medical Spending in 2020, By Region, (% of Total)
  • Figure 17: Most frequent neurological diseases reported in primary care, In 2017
  • Figure 18: Most frequent neurological diseases reported in primary care, In 2017
  • Figure 19: Regional Expected Healthcare Industry Growth Rate By Year 2020
  • Figure 20: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
  • Figure 21: Projected global population aged 60 years & above (In Billions)
  • Figure 22: Global Central Nervous System Therapeutic Market Size, By Type, 2017 (In %)
  • Figure 23: Global Central Nervous System Therapeutic Market Size, By Type, 2023 (In %)
  • Figure 24: Global Cancer Market, By Value, 2014-2018 (USD Billion)
  • Figure 25: Global Cancer Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 26: Global Neurovascular Market, By Value, 2014-2018 (USD Billion)
  • Figure 27: Global Neurovascular Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 28: Global Neurodegenerative Market, By Value, 2014-2018 (USD Billion)
  • Figure 29: Global Neurodegenerative Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 30: Global Neurodegenerative Therapeutic Market Size, By Value, 2018 (%)
  • Figure 31: Global Neurodegenerative Therapeutic Market Size, By Value, 2024 (%)
  • Figure 32: Global Mental Health Market, By Value, 2014-2018 (USD Billion)
  • Figure 33: Global Mental Health Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 34: Global Trauma Market, By Value, 2014-2018 (USD Billion)
  • Figure 35: Global Trauma Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 36: Global TraumaTherapeutic Market Size, By Value, 2018 (%)
  • Figure 37: Global TraumaTherapeutic Market Size, By Value, 2024 (%)
  • Figure 38: Global Brain Infection Market, By Value, 2014-2018 (USD Billion)
  • Figure 39: Global Brain Infection Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 40: Global Healthcare Landscape, By Select Region
  • Figure 41: Global Central Nervous System Therapeutic Market Size, By Region, 2018 (%)
  • Figure 42: Global Central Nervous System Therapeutic Market Size, By Region, 2024 (%)
  • Figure 43: North America Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 44: North America Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
  • Figure 45: North America Population Ages 65 and above, 2012-2017 (% of Total)
  • Figure 46: North America Healthcare Cost Per Capita, 2017 (USD)
  • Figure 47: Most frequent neurological diseases reported in primary care, In North America, 2017
  • Figure 48: North America GDP, 2012-2017 (USD Trillion)
  • Figure 49: North America GDP per capita, current prices, 2013-2023F (In USD)
  • Figure 50: North America Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
  • Figure 51: North America Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
  • Figure 52: U.S. Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 53: U.S. Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 54: Most costly neurological disorders in United States, In 2017
  • Figure 55: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
  • Figure 56: Proportion of people with Alzheimer disease, In United States, In 2017
  • Figure 57: Projected number of people with Alzheimer disease aged 65 and older, In United States, In million, In 2017
  • Figure 58: Aggregate cost of care for Alzheimer, By payer, In United States, In 2017
  • Figure 59: U.S., Population ages 65 and above, Forecast (In Millions)
  • Figure 60: U.S., GDP (Current USD), 2014-2018 (In USD Trillion)
  • Figure 61: Canada Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 62: Canada Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 63: Canada, Population ages 65 and above, 2012-2017 (% of total)
  • Figure 64: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
  • Figure 65: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
  • Figure 66: Incidence, mortality and survival statistics for brain cancer in Canada, In 2017
  • Figure 67: Prevalence of brain cancer in Canada
  • Figure 68: Europe Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 69: Europe Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
  • Figure 70: Most frequent neurological diseases reported in primary care, In Europe, 2017
  • Figure 71: Distribution of Schizophrenia patients worldwide, In 2017, In thousands
  • Figure 72: Per Capita Health Expenditure, By Select Country, 2017 (USD)
  • Figure 73: European Union, Population ages 65 and above, 2013-2017 (% of total)
  • Figure 74: European Country Population Aged 65 and Above, 2012-2017 (% of Total)
  • Figure 75: GDP, Europe Region, By Select Country, 2017 (In Trillion USD)
  • Figure 76: Europe Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
  • Figure 77: Europe Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
  • Figure 78: U.K. Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 79: U.K. Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 80: Most costly neurological disorders in United Kingdom, In 2017
  • Figure 81: Proportion of people with symptoms of mental disorders in United Kingdom
  • Figure 82: Proportion of symptoms of mental disorder, By sex, In 2017, In United Kingdom
  • Figure 83: U.K, Health Expenditure, (% of GDP), 2012-2017 (USD)
  • Figure 84: U.K, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 85: UK, Healthcare Infrastructure Related Statistics
  • Figure 86: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
  • Figure 87: Germany Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 88: Germany Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 89: Germany, Population ages 65 and above, 2012-2017 (% total)
  • Figure 90: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
  • Figure 91: Germany, Healthcare Related Statistics, 2017
  • Figure 92: APAC Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 93: APAC Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
  • Figure 94: GDP Per Capita in APAC, By Select Country, 2016 (In USD)
  • Figure 95: Population ages 65 and above, By Select Country, 2017 (% of total)
  • Figure 96: Men Smoking Prevalence in Asia, 2016, (% of Total Population)
  • Figure 97: Most frequent neurological diseases reported in primary care, In Asia Pacific, 2017
  • Figure 98: APAC Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
  • Figure 99: APAC Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
  • Figure 100: China Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 101: China Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 102: China, Smoking Prevalence, Age 15+, % of Total Population, 2012-2016
  • Figure 103: China, Tobacco Attributable Deaths, 2030
  • Figure 104: China, Total Population, 2013-2021F (In Billion)
  • Figure 105: China, GDP Growth Per Year, 2015-2019 (In %)
  • Figure 106: China, Share of Urban Population, 2012-2017 (In %)
  • Figure 107: China Healthcare Expenditure Outlook (2017) (%)
  • Figure 108: China, Population Above 65 (% of Total), 2013-2017
  • Figure 109: Japan Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 110: Japan Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 111: Japan, Population ages 65 and above, 2012-2017 (% of total)
  • Figure 112: Japan, Smoking Prevalence, Age 15+, 2012-2016, (% of Total Prevalence)
  • Figure 113: Japan Healthcare Expenditure Outlook (%)
  • Figure 114: India Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 115: India Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 116: India, Population ages 65 and above, 2013-2017
  • Figure 117: India, Total Population, 2013-2023F (In Billion)
  • Figure 118: India, Smoking Prevalence, Age 15+, 2012-2016, (% of Total)
  • Figure 119: India, Share of Urban Population, 2012-2017 (In %)
  • Figure 120: India, GDP Growth Per Year, 2015-2019 (In %)
  • Figure 121: ROW Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 122: ROW Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
  • Figure 123: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
  • Figure 124: GDP Per Capita in ROW, By Select Country, 2017 (In USD)
  • Figure 125: Latin America and Caribbean, Population ages 65 and above 2012-2017(% of total)
  • Figure 126: Middle East and North Africa, Population ages 65 and above (% of total)
  • Figure 127: Most frequent neurological diseases reported in primary care, In Africa, In 2017
  • Figure 128: Methods of financing neurological care
  • Figure 129: ROW Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
  • Figure 130: ROW Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
  • Figure 131: Brazil Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 132: Brazil Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 133: Brazil, Population ages 65 and above, 2012-17 (% of total)
  • Figure 134: Brazil, GDP, 2012-2017 (In USD Trillion)
  • Figure 135: Brazil health expenditure as a share of GDP, 2016
  • Figure 136: Biogen, Sales Revenue, 2013-2017 (USD Billion)
  • Figure 137: Biogen, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 138: Biogen, Sales, By Geographic region, FY ended March 2017 (%)
  • Figure 139: Pfizer, Sales Revenue, 2013-2017 (USD million)
  • Figure 140: Pfizer, Sales, By Business Segment, FY ended March 2017 (In %)
  • Figure 141: Pfizer, By Geographic Region, FY ended March 2017 (In %)
  • Figure 142: Teva Pharmaceuticals, Net Sales, 2014-2018 (In Million USD)
  • Figure 143: Teva Pharmaceuticals, Net Sales, By Business Sector, 2018 (In %)
  • Figure 144: Teva Pharmaceuticals, Net Sales, By Geographic Region, 2018 (In %)
  • Figure 145: Novartis, Sales Revenue, 2013-2017 (USD Million)
  • Figure 146: Novartis, Sales, By Business Segment, FY ended March 2018 (%)
  • Figure 147: Novartis, By Region, FY ended March 2018 (%)
  • Figure 148: Johnson & Johnson, Sales Revenue, 2013-2017 (USD Million)
  • Figure 149: Johnson & Johnson , Sales, By Business Segment, FY ended March 2018 (%)
  • Figure 150: Johnson & Johnson, By Region, FY ended March 2018 (%)
  • Figure 151: Shire, Sales Revenue, 2015-2017 (USD Million)
  • Figure 152: Shire, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 153: Shire, By Region, FY ended March 2017 (%)
  • Figure 154: Merck & Co., Sales Revenue, 2013-2017 (USD Million)
  • Figure 155: Merck & Co. , Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 156: Merck & Co., By Region, FY ended March 2017 (%)
  • Figure 157: AstraZeneca, Sales Revenue, 2013-2017 (USD Million)
  • Figure 158: AstraZeneca, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 159: AstraZeneca, By Region, FY ended March 2017 (%)
  • Figure 160: Otsuka Pharmaceutical, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 161: Otsuka Pharmaceutical, By Region, FY ended March 2017 (%)
  • Figure 162: Eli Lilly, Sales Revenue, 2013-2017 (USD Million)
  • Figure 163: Eli Lilly, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 164: Eli Lilly, By Region, FY ended March 2017 (%)

List of Tables

  • Table A: Top 10 diseases causing the most deaths worldwide, In 2017
  • Table B: Smoking prevalence worldwide, In 2017, By Sex, In %
  • Table C: Facts about mental health in United Kingdom
  • Table D: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
  • Table E: Rate of suicides worldwide, In 2017, In number
  • Table F: National List of Essential medicines in India, By Select Disease, In 2017
  • Table G: Healthcare spending pattern in Brazil (In USD)
目次

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Central nervous System Therapeutic Market. The report analyzes the Central Nervous System Therapeutic Market By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection). The Central Nervous System Therapeutic Market has been analyzed By Region (North America, Europe, Asia Pacific and Rest of the World) and By Country (US, Canada, UK, Germany, China, Japan, India, and Brazil) for the historical period of 2014-2018 and the forecast period of 2019-2024.

According to Azoth Analytics research report "Global Central Nervous System Therapeutic Market : Analysis By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma and Infection), By Region, By Country (2019 Edition): Opportunities and Forecast (2014-2024) - By Region (North America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, China, Japan, India, Brazil)", global market is projected to display a robust growth represented by a CAGR of 6.80% during 2019 - 2024.

The mental health has been witnessing growth at a noteworthy rate over the past few years backed by rise in stress and depression among people as well as increasing awareness and acceptance amongst people about mental health. Amongst the regions, Asia Pacific accounts for the largest regional share in the global central nervous system therapeutic market in 2018. Key factors driving the robust growth rate of Asia Pacific region include rising geriatric population along with increasing incidences of neurodegenerative diseases, increase in chronic ailments and growing per capita healthcare expenditure worldwide.

The report titled "Global Central Nervous System Therapeutic Market: Analysis By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma and Infection), By Region, By Country (2019 Edition): Opportunities and Forecast (2014-2024) - By Region (North America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, China, Japan, India, Brazil)" has covered and analyzed the potential of Global Central Nervous System Therapeutic market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global central nervous system therapeutic market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Central Nervous System Therapeutic Market (Actual Period: 2014-2018, Forecast Period: 2019-2024

  • Global Central Nervous System Therapeutic Market - Size, Growth, Forecast
  • By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection)

Regional Markets - North America, Europe, APAC and Rest of the World (Actual Period: 2014-2018, Forecast Period: 2019-2024)

  • Central Nervous System Therapeutic Market - Size and Growth
  • By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection)

Country Analysis - US, Canada, UK, Germany, China, Japan, India, Brazil (Actual Period: 2014-2018, Forecast Period: 2019-2024)

  • Central Nervous System Therapeutic Market - Size and Growth
  • By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection)

Other Report Highlights

  • Market Dynamics - Drivers and Restraints
  • Market Trends
  • Porter Five Force Analysis
  • Policy and Regulatory Landscape
  • Competitive Landscape
  • Company Analysis - Biogen, Pfizer, Teva Pharmaceuticals, Novartis, Johnson & Johnson, Shire, Merc & Co, AstraZeneca, Otsuka Pharmaceutical, Eli Lilly.

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Central Nervous System Therapeutic Market: Product Outlook

5. Global Central Nervous System Therapeutic Market: Growth and Forecast

  • 5.1 By Value (2014-2018)
  • 5.2 By Value (2019-2024)

6. Global Central Nervous System Therapeutic Market: Segment Analysis

  • 6.1 Global Central Nervous System Therapeutic Market Size, By Type: Breakdown (%)
    • 6.1.1 Global Central Nervous System Therapeutic Market Size, By Type, 2018 (%)
    • 6.1.2 Global Central Nervous System Therapeutic Market Size, By Type, 2024 (%)
  • 6.2 Global Cancer Market, By Value (2014-2024)
  • 6.3 Global Neurovascular Market, By Value (2014-2024)
  • 6.4 Global Neurodegenerative disorder Market, By Value (2014-2024)
  • 6.5 Global Mental Health Market, By Value (2014-2024)
  • 6.6 Global Trauma Market, By Value(2014-2024)
  • 6.7 Global Infection Market, By Value (2014-2024)

7. Global Central Nervous System Therapeutic Market: Regional Analysis

  • 7.1 Global Central Nervous System Therapeutic Market Size, By Region: Breakdown (%)
    • 7.1.1 Global Central Nervous System Therapeutic Market Size, By Region, 2018 (%)
    • 7.1.2 Global Central Nervous System Therapeutic Market Size, By Region, 2024 (%)
  • 7.2 North America Central Nervous System Therapeutic Market: Growth and Forecast
    • 7.2.1 By Value (2014-2018)
    • 7.2.2 By Value (2019-2024)
    • 7.2.3 By Type, By Value (2014-2018)
    • 7.2.4 By Type, By Value (2019-2024)
  • 7.3 North America Central Nervous System Therapeutic Market: Country Analysis (U.S and Canada)
    • 7.3.1 U.S Central Nervous System Therapeutic Market, By Value (2014-2024)
    • 7.3.2 Canada Central Nervous System Therapeutic Market, By Value (2014-2024)
  • 7.4 Europe Central Nervous System Therapeutic Market: Growth and Forecast
    • 7.4.1 By Value (2014-2018)
    • 7.4.2 By Value (2019-2024)
    • 7.4.3 By Type, By Value (2014-2018)
    • 7.4.4 By Type, By Value (2019-2024)
  • 7.5 Europe Central Nervous System Therapeutic Market: Country Analysis (U.K and Germany)
    • 7.5.1 U.K Central Nervous System Therapeutic Market, By Value (2014-2024)
    • 7.5.2 Germany Central Nervous System Therapeutic Market, By Value (2014-2024)
  • 7.6 APAC Central Nervous System Therapeutic Market: Growth and Forecast
    • 7.6.1 By Value (2014-2018)
    • 7.6.2 By Value (2019-2024)
    • 7.6.3 By Type, By Value (2014-2018)
    • 7.6.4 By Type, By Value (2019-2024)
  • 7.7 APAC Central Nervous System Therapeutic Market: Country Analysis (Japan, India and China)
    • 7.7.1 China Central Nervous System Therapeutic Market, By Value (2014-2024)
    • 7.7.2 Japan Central Nervous System Therapeutic Market, By Value (2014-2024)
    • 7.7.3 India Central Nervous System Therapeutic Market, By Value (2014-2024)
  • 7.8 ROW Central Nervous System Therapeutic Market: Growth and Forecast
    • 7.8.1 By Value (2014-2018)
    • 7.8.2 By Value (2019-2024)
    • 7.8.3 By Type, By Value (2014-2018)
    • 7.8.4 By Type, By Value (2019-2024)
  • 7.9 ROW Central Nervous System Therapeutic Market: Country Analysis (Brazil)
    • 7.9.1 Brazil Central Nervous System Therapeutic Market, By Value (2014-2024)

8. Global Central Nervous System Therapeutic Market Dynamics

  • 8.1 Global Central Nervous System Therapeutic Market Drivers
  • 8.2 Global Central Nervous System Therapeutic Market Restraints

9. Global Central Nervous System Therapeutic Market Trends

10. Porter Five Force Analysis

11. SWOT Analysis

12. Supply Chain Analysis

13. Policy and Regulatory Landscape

14. Company Profiles

  • 14.1 Biogen
  • 14.2 Pfizer
  • 14.3 Teva Pharmaceuticals
  • 14.4 Novartis
  • 14.5 Johnson & Johnson
  • 14.6 Shire
  • 14.7 Merck & Co.
  • 14.8 AstraZeneca
  • 14.9 Otsuka Pharmaceutical
  • 14.10 Eli Lilly
Back to Top